ABBV-951은 AbbVie가 개발 중인 포스 레보도파/포스카르비도파 함유 임상시험용 약물입니다. 카르비도파와 레보도파의 프로드러그를 지속적으로 피하 투여하는 용액으로, 진행성 파킨슨병 환자의 운동기능 변동에 대한 치료제로 검토되고 있습니다. 이 약은 도파민 수용체를 표적으로 하는 저분자 화합물입니다.
CD/LD를 24시간 동안 지속적으로 피하 투여할 수 있도록 설계되었습니다. 경구용 CD/LD와 비교하여 진행성 파킨슨병 환자의 운동 이상증상을 개선할 수 있습니다. 진행성 파킨슨병은 도파민을 생성하는 뇌세포의 소실로 인해 발생하는 진행성 만성 신경질환으로 주로 떨림, 근육 경직, 운동 둔화, 균형 장애를 나타냅니다.
최근 AbbVie는 ABBV-951(포스칼비도파/포스레보도파)의 신약허가신청(NDA)에 대한 심사 완료 보고서(CRL)를 받았습니다. AbbVie는 임상 3상 시험인 M15-736 시험의 데이터를 바탕으로 신약 허가 신청서를 제출했습니다.
앞으로 몇 년동안 파킨슨병 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 증가로 인해 변화할 것입니다. 각 업체들은 질병을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, ABBV-951의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다.
다른 파킨슨병 치료제들도 ABBV-951과 치열한 시장 경쟁을 펼칠 것으로 예상되며, 조만간 후발주자 신약이 출시되면 시장에 큰 영향을 미칠 것으로 보입니다.
이 보고서는 주요 7개국의 파킨슨병 치료제 ABBV-951 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.
목차
제1장 보고서 서론
제2장 파킨슨병에서의 ABBV-951개요
- 제품 상세
- 임상 개발
- 규제 마일스톤
- 기타 개발 활동
- 제품 개요
제3장 경쟁 구도(출시 치료법)
제4장 경쟁 구도(후기 단계 신흥 치료법)
제5장 ABBV-951 시장 평가
- 파킨슨병용 ABBV-951 시장 전망
- 주요 7개국 분석
- 주요 7개국의 파킨슨병 치료제 ABBV-951 시장 규모
- 국가별 시장 분석
제6장 SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight에 대해
제12장 보고서 구입 옵션
LSH
"ABBV-951 Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about ABBV-951 for Parkinson's disease in the seven major markets. A detailed picture of the ABBV-951 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ABBV-951 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ABBV-951 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.
Drug Summary:
ABBV-951 is an investigational drug-containing foslevodopa /foscarbidopa being developed by AbbVie. It is a solution of carbidopa and levodopa prodrugs for continuous subcutaneous delivery that is being investigated for the treatment of motor fluctuations in patients with advanced Parkinson's disease. It is a small molecule that targets dopamine receptors.
It is designed to provide 24-hour, continuous subcutaneous delivery of CD/LD. Compared to oral CD/LD, it offers the potential for improvement in motor fluctuations in patients with advanced Parkinson's disease, a progressive and chronic neurological disorder resulting from the loss of dopamine-producing brain cells, which primarily manifests with tremor, muscle rigidity, slowness of movement and difficulty with balance.
Recently, AbbVie received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ABBV-951 (foscarbidopa/foslevodopa). It had submitted NDA based on data from the M15-736 study, a Phase III trial.
Scope of the Report:
The report provides insights into:
- A comprehensive product overview including the ABBV-951 description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
- Elaborated details on ABBV-951 regulatory milestones and other development activities have been provided in this report.
- The report also highlights the ABBV-951 research and development activities in Parkinson's disease across the United States, Europe and Japan.
- The report also covers the patents information with expiry timeline around ABBV-951.
- The report contains forecasted sales of ABBV-951 for Parkinson's disease till 2032.
- Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
- The report also features the SWOT analysis with analyst views for ABBV-951 in Parkinson's disease.
Methodology:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ABBV-951 Analytical Perspective by DelveInsight
- In-depth ABBV-951 Market Assessment
This report provides a detailed market assessment of ABBV-951 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
- ABBV-951 Clinical Assessment
The report provides the clinical trials information of ABBV-951 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights:
- In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ABBV-951 dominance.
- Other emerging products for Parkinson's disease are expected to give tough market competition to ABBV-951 and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ABBV-951 in Parkinson's disease.
- Our in-depth analysis of the forecasted sales data of ABBV-951 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ABBV-951 in Parkinson's disease.
Key Questions:
- What is the product type, route of administration and mechanism of action of ABBV-951?
- What is the clinical trial status of the study related to ABBV-951 in Parkinson's disease and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ABBV-951 development?
- What are the key designations that have been granted to ABBV-951 for Parkinson's disease?
- What is the forecasted market scenario of ABBV-951 for Parkinson's disease?
- What are the forecasted sales of ABBV-951 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
- What are the other emerging products available and how are these giving competition to ABBV-951 for Parkinson's disease?
- Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?
Table of Contents
1. Report Introduction
2. ABBV-951 Overview in Parkinson's disease
- 2.1. Product Detail
- 2.2. Clinical Development
- 2.2.1. Clinical studies
- 2.2.2. Clinical trials information
- 2.2.3. Safety and Efficacy
- 2.3. Regulatory Milestones
- 2.4. Other Developmental Activities
- 2.5. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. ABBV-951 Market Assessment
- 5.1. Market Outlook of ABBV-951 in Parkinson's disease
- 5.2. 7MM Analysis
- 5.2.1. Market Size of ABBV-951 in the 7MM for Parkinson's disease
- 5.3. Country-wise Market Analysis
- 5.3.1. Market Size of ABBV-951 in the United States for Parkinson's disease
- 5.3.2. Market Size of ABBV-951 in Germany for Parkinson's disease
- 5.3.3. Market Size of ABBV-951 in France for Parkinson's disease
- 5.3.4. Market Size of ABBV-951 in Italy for Parkinson's disease
- 5.3.5. Market Size of ABBV-951 in Spain for Parkinson's disease
- 5.3.6. Market Size of ABBV-951 in the United Kingdom for Parkinson's disease
- 5.3.7. Market Size of ABBV-951 in Japan for Parkinson's disease
6. SWOT Analysis
7. Analysts' Views
8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
12. Report Purchase Options
